Sorafenib in advanced iodine‐refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and <scp>FDG</scp>‐<scp>PET</scp>

Abstract

Sorafenib allows morphological disease control in the majority of patients with iodine-refractory DTC. Progression-free survival and overall survival were lower than in previous studies as a consequence of the worse clinical condition of our patients. Sorafenib is mostly well tolerated but could have been responsible for the reported fatal events. Baseline Tg and the Tg response to treatment could be useful for predicting morphological response and clinical outcome. Early FDG-PET response could be helpful for the timely identification of nonresponding patients.